KD

Karolinska Development ABSTO Karolinska Development Stock Report

Last reporting period 30 Jun, 2024

Updated 01 Nov, 2024

Last price

Market cap $B

0.032

Micro

Exchange

XSTO - Nasdaq STOCKHOLM AB

KDEV.ST Stock Analysis

KD

Uncovered

Karolinska Development AB is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-15/100

Low score

Market cap $B

0.032

Dividend yield

Shares outstanding

269.83 B

Karolinska Development AB engages in the investment in pharmaceutical and medical technology companies. The company is headquartered in Solna, Stockholm. The company went IPO on 2011-04-15. The firm provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.

View Section: Eyestock Rating